All In MedTech

FDA Clearance Tracker · P050028

COBAS TAQMAN HBV TEST

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Sep 4, 2008 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

The decision

FDA number
P050028
Device name
COBAS TAQMAN HBV TEST
Applicant location
Pleasanton, CA
Received
Aug 2, 2005
Decided
Sep 4, 2008
Decision
Approved (reclassified)
Supplements
88 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3174

Every decision under product code MKT

FDA's approval statement

As written in FDA's record.

APPROVAL FOR COBAS TAQMAN HBV TEST FOR USE WITH THE HIGH PURE SYSTEM. THIS DEVICE IS INDICATED FOR: THE COBAS TAQMAN HBV TEST FOR USE WITH THE HIGH PURE SYSTEM IS AN IN VITRO NUCLEIC ACID AMPLIFICATION TEST FOR THE QUANTITATION OF HEPATITIS B VIRUS (HBV) DNA IN HUMAN SERUM OR PLASMA (EDTA), USING THE HIGH PURE VIRAL NUCLEIC ACID KIT FOR MANUAL SPECIMEN PREPARATION AND THE COBAS TAQMAN 48 ANALYZER FOR AUTOMATED AMPLIFICATION AND DETECTION. THE TEST IS INTENDED FOR USE AS AN AID IN THE MANAGEMENT OF PATIENTS WITH CHRONIC HBV INFECTION UNDERGOING ANTI-VIRAL THERAPY. THE ASSAY CAN BE USED TO MEASURE HBV DNA LEVELS AT BASELINE AND DURING TREATMENT TO AID IN ASSESSING RESPONSE TO TREATMENT. THE RESULTS FROM THE COBAS TAQMAN HBV TEST MUST BE INTERPRETED WITHIN THE CONTEXT OF ALL RELEVANT CLINICAL AND LABORATORY FINDINGS. ASSAY PERFORMANCE CHARACTERISTICS HAVE BEEN ESTABLISHED FOR INDIVIDUALS TREATED WITH ADEFOVIR DIPIVOXIL. ASSAY PERFORMANCE FOR DETERMINING THE STATE OF HBV INFECTION HAS NOT BEEN ESTABLISHED. THE COBAS TAQMAN HBV TEST IS NOT INTENDED FOR USE AS A SCREENING TEST FOR BLOOD OR BLOOD PRODUCTS FOR THE PRESENCE OF HBV OR AS A DIAGNOSTIC TEST TO CONFIRM THE PRESENCE OF HBV INFECTION.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code MKT (Hepatitis Viral B DNA Detection).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Roche Molecular Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.